profit from every $100 of sales.
$0$100
Tianjin Pharmaceutical Da Ren Tang Group
$2.53-0.78% today
-24.0% since Dec 19, 25
1-year low $2.471-year high $3.66
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay $10.20 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Tianjin Pharmaceutical Da Ren Tang Group vs. similar companies
Tianjin Pharmaceutical Da Ren Tang Group grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tianjin Pharmaceutical Da Ren Tang Group | 10.2× · Cheap | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Tianjin Pharmaceutical Da Ren Tang Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 10.2×
- –
- 0.29
- 3.2×
- 4.4×
- 63.5×
- –
- 1.6%
- 9.8%
- –
Profitability
- 74.0%
- 19.7%
- 43.3%
- –
- 28.9%
- 20.6%
- –
- –
- –
- –
Growth
- −15.8%
- +35.6%
- –
- –
- −0.3%
Financial health
- -0.4×
- 0.01
- –
- 272.5×
- 1.59
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 4%of 964
Top 27%of 898
Top 9%of 651
Bottom 5%of 911
Bottom 49%of 991
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
7/7Passes 7 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
74Pass
Benjamin Graham
70Pass
Philip Fisher
81Pass
Peter Lynch
91Pass
Joel Greenblatt
75Pass
Charlie Munger
86Pass
Terry Smith
69Pass
Questions about Tianjin Pharmaceutical Da Ren Tang Group
Is Tianjin Pharmaceutical Da Ren Tang Group a good stock to buy?
A strong, very profitable business, and the price looks low. 7 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tianjin Pharmaceutical Da Ren Tang Group AI analysis
What does Tianjin Pharmaceutical Da Ren Tang Group do?
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It is in Drug Manufacturers - Specialty & Generic.
Is Tianjin Pharmaceutical Da Ren Tang Group stock halal?
Yes. Tianjin Pharmaceutical Da Ren Tang Group passes our halal screen: its business is permitted and its debt is 0.3% of its market value, under the 30% limit. How we check
Who are Tianjin Pharmaceutical Da Ren Tang Group's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Tianjin Pharmaceutical Da Ren Tang Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.